Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q8N1B3
UPID:
CCNQ_HUMAN
Alternative names:
CDK10-activating cyclin; Cyclin-M; Cyclin-related protein FAM58A
Alternative UPACC:
Q8N1B3; Q2I380; Q330J9; Q96IU5; Q9BUU1
Background:
Cyclin-Q, also known as CDK10-activating cyclin, Cyclin-M, and Cyclin-related protein FAM58A, plays a pivotal role in cell cycle regulation by activating the cyclin-associated kinase CDK10. This activation is crucial for the proper progression of the cell cycle, impacting cell division and growth.
Therapeutic significance:
Cyclin-Q is implicated in the syndrome characterized by toe syndactyly, telecanthus, and anogenital and renal malformations. Understanding the role of Cyclin-Q could open doors to potential therapeutic strategies for this complex syndrome, highlighting its significance in genetic and developmental research.